Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis.

Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Tolédano C, Cabane J, Dinh-Xuan AT.

Eur Respir J. 2011 Dec;38(6):1355-60. doi: 10.1183/09031936.00004711. Epub 2011 Jul 20.

2.

Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?

Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada-Y-Martin RM, Gonzalez EB, Lewis DE, Draeger HT, Kim S, Arnett FC, Mayes MD, Assassi S.

J Rheumatol. 2013 Jul;40(7):1114-20. doi: 10.3899/jrheum.120997. Epub 2013 Apr 15.

3.

Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.

Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Müller-Quernheim J.

Am J Respir Crit Care Med. 2009 Apr 15;179(8):717-23. doi: 10.1164/rccm.200808-1201OC. Epub 2009 Jan 29.

PMID:
19179488
4.

Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma.

Tiev KP, Hua-Huy T, Kettaneh A, Allanore Y, Le-Dong NN, Duong-Quy S, Cabane J, Dinh-Xuan AT.

Thorax. 2012 Feb;67(2):157-63. doi: 10.1136/thoraxjnl-2011-200499. Epub 2011 Oct 24.

PMID:
22026971
5.

High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis.

Hoffmann-Vold AM, Tennøe AH, Garen T, Midtvedt Ø, Abraityte A, Aaløkken TM, Lund MB, Brunborg C, Aukrust P, Ueland T, Molberg Ø.

Chest. 2016 Aug;150(2):299-306. doi: 10.1016/j.chest.2016.03.004. Epub 2016 Mar 18.

PMID:
26997242
6.

Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas.

Plönes T, Krohn A, Burger M, Veelken H, Passlick B, Müller-Quernheim J, Zissel G.

PLoS One. 2012;7(7):e41746. doi: 10.1371/journal.pone.0041746. Epub 2012 Jul 25.

7.

Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.

Muangchan C, Harding S, Khimdas S, Bonner A; Canadian Scleroderma Research group, Baron M, Pope J.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1405-14. doi: 10.1002/acr.21716.

8.

Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis.

Schupp J, Becker M, Günther J, Müller-Quernheim J, Riemekasten G, Prasse A.

Eur Respir J. 2014 May;43(5):1530-2. doi: 10.1183/09031936.00131713. No abstract available.

9.

Aldolase predicts subsequent myopathy occurrence in systemic sclerosis.

Tolédano C, Gain M, Kettaneh A, Baudin B, Johanet C, Chérin P, Rivière S, Cabane J, Tiev KP.

Arthritis Res Ther. 2012 Jun 22;14(3):R152. doi: 10.1186/ar3888.

10.

Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U.

Respir Med. 2014 Jul;108(7):1031-9. doi: 10.1016/j.rmed.2014.04.009. Epub 2014 Apr 26.

11.

Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.

Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM; Scleroderma Lung Study Research Group.

J Rheumatol. 2009 Apr;36(4):773-80. doi: 10.3899/jrheum.080633. Epub 2009 Mar 13.

PMID:
19286849
12.

Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.

Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Sasaki T, Takahashi H, Tanaka S, Takehara K, Sato S.

Rheumatology (Oxford). 2012 Jan;51(1):129-33. doi: 10.1093/rheumatology/ker333. Epub 2011 Nov 9.

PMID:
22072085
13.

Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease.

Hesselstrand R, Andréasson K, Wuttge DM, Bozovic G, Scheja A, Saxne T.

Rheumatology (Oxford). 2012 May;51(5):915-20. doi: 10.1093/rheumatology/ker442. Epub 2012 Jan 16.

PMID:
22253028
14.

Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion.

van Lieshout AW, Vonk MC, Bredie SJ, Joosten LB, Netea MG, van Riel PL, Lafyatis R, van den Hoogen FH, Radstake TR.

Scand J Rheumatol. 2009;38(4):282-90. doi: 10.1080/03009740802572467.

PMID:
19255934
15.

CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.

Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Müller-Quernheim J.

Arthritis Rheum. 2007 May;56(5):1685-93.

16.

CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms.

Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, Haspels I, Putter H, van Berkel TJ, Nagelkerken L, Jukema JW, Biessen EA.

Circulation. 2007 Oct 23;116(17):1931-41. Epub 2007 Oct 1.

17.

Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.

Hanke K, Dähnrich C, Brückner CS, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Hiepe F, Burmester GR, Schlumberger W, Riemekasten G.

Arthritis Res Ther. 2009;11(1):R28. doi: 10.1186/ar2622. Epub 2009 Feb 21.

18.

Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.

Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P.

J Rheumatol. 2001 Nov;28(11):2454-9.

PMID:
11708418
19.

CCL18 -- potential biomarker of fibroinflammatory activity in chronic periaortitis.

Kollert F, Binder M, Probst C, Uhl M, Zirlik A, Kayser G, Voll RE, Peter HH, Zissel G, Prasse A, Warnatz K.

J Rheumatol. 2012 Jul;39(7):1407-12. doi: 10.3899/jrheum.111143. Epub 2012 May 15.

PMID:
22589264
20.

Serum CCL23 levels are increased in patients with systemic sclerosis.

Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, Sato S.

Arch Dermatol Res. 2011 Jan;303(1):29-34. doi: 10.1007/s00403-010-1078-8. Epub 2010 Sep 8.

PMID:
20824279

Supplemental Content

Support Center